` DBVT (DBV Technologies SA) vs S&P 500 Comparison - Alpha Spread

DBVT
vs
S&P 500

Over the past 12 months, DBVT has significantly outperformed S&P 500, delivering a return of +179% compared to the S&P 500's +11% growth.

Stocks Performance
DBVT vs S&P 500

Loading
DBVT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
DBVT vs S&P 500

Performance Gap Between DBVT and GSPC
HIDDEN
Show

Performance By Year
DBVT vs S&P 500

Loading
DBVT
S&P 500
Add Stock

Competitors Performance
DBV Technologies SA vs Peers

S&P 500
DBVT
ABBV
AMGN
GILD
VRTX
Add Stock

DBV Technologies SA
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBVT Intrinsic Value
HIDDEN
Show
Back to Top